Related Experiment Videos
Fludarabine therapy in macroglobulinemic lymphoma
H M Kantarjian1, R Alexanian, C A Koller
1Department of Hematology, University of Texas M.D. Anderson Cancer Center, Houston 77030.
Blood
|May 15, 1990
Summary
Fludarabine effectively treated macroglobulinemic lymphoma in patients resistant to chemotherapy. This nucleoside analogue showed significant tumor reduction, indicating its potential as a valuable therapeutic agent.
Area of Science:
- Oncology
- Hematology
- Pharmacology
Background:
- Macroglobulinemic lymphoma is a rare B-cell malignancy.
- Patients often exhibit resistance to standard chemotherapy regimens.
- Limited effective treatment options exist for refractory cases.
Purpose of the Study:
- To evaluate the efficacy of fludarabine in patients with macroglobulinemic lymphoma.
- To assess treatment response and duration in a heavily pretreated patient cohort.
Main Methods:
- Eleven patients with macroglobulinemic lymphoma received fludarabine.
- Most patients had previously failed standard chemotherapy.
- Response was defined by a reduction in immunoglobulin M (IgM) tumor mass.
Main Results:
- Five patients (45%) achieved a >50% reduction in IgM tumor mass.
- The median duration of remission was projected to exceed 1 year.
- Responding patients showed a median tumor halving time of 5.2 months, suggesting slow but persistent response.
Conclusions:
- Fludarabine demonstrates significant activity against macroglobulinemic lymphoma.
- Repeated treatment courses are important due to the slow onset of remission.
- Further evaluation of fludarabine in combination therapies is warranted.